1. Introduction {#sec0005}
===============

Needle biopsies have become the preferred method for the initial evaluation of breast lesions. Patients with benign findings are spared surgical excision and patients with malignant findings can have definitive surgery planned. There has been a long-standing concern about the possibility of needle track seeding leading to local breast cancer recurrence [@bib0005]. Fortunately, recurrences in the needle track are exceedingly rare. We report the case of a woman treated for ductal carcinoma in situ DCIS and one focus of microinvasion with mastectomy and autologous reconstruction, who recurred with DCIS involving the epidermis (Paget disease of the skin) at the skin puncture site of the original core needle biopsy.

2. Case report {#sec0010}
==============

A 38 year old woman at high risk of breast cancer due to prior radiation for Hodgkin disease was discovered to have an area of calcifications in the lower inner quadrant of the right breast on her first screening mammogram. No skin lesions were present and the nipple was normal in appearance. A 10 gauge vacuum-assisted core needle biopsy successfully sampled the calcifications and a marking clip was placed. The needle entered the breast at approximately 5:00 ([Fig. 1](#fig0005){ref-type="fig"}). The biopsy revealed high grade DCIS with comedo necrosis and calcifications. A single focus was suspicious for microinvasion. The DCIS was negative for estrogen receptor (ER), showed 1--4% positivity for progesterone receptor (PR), and was positive for HER2 (3+). Breast MRI showed a corresponding 2.5 × 1.0 cm area of enhancement in the area of the DCIS, located 5.3 cm away from the nipple.

The patient opted to undergo bilateral skin sparing mastectomies with immediate reconstruction using pedicled transverse rectus abdominus myocutaneous (TRAM) flaps. The nipple and areolar complexes were removed, but the skin in the area of the prior needle biopsy site was preserved. The right mastectomy revealed DCIS with 2 foci of microinvasion over 3--4 cm. The skin, nipple, superficial skin flap margin, and deep margin were free of carcinoma, as were 3 sentinel nodes.

One and a half years after the mastectomy, the patient noted an area of skin change in the lower inner aspect of the right reconstructed breast ([Fig. 2](#fig0010){ref-type="fig"}). This area was not close to the mastectomy scar or the reconstructed nipple. The lesion measured 1.2 cm but gradually increased in size and was treated by her primary care physician with topical antifungal medication. The skin lesion continued to enlarge and was brought to the attention of her breast surgical oncologist three years after her mastectomy. The erythematous lesion now measured 2.5 × 2.0 cm and appeared eroded ([Fig. 3](#fig0015){ref-type="fig"}). Photographs taken by her plastic surgeon prior to her mastectomy and reconstruction fortuitously showed the skin puncture site of the original core needle biopsy ([Fig. 1](#fig0005){ref-type="fig"}). It was apparent that the skin lesion was at this same site. A skin punch biopsy was performed and revealed tumor cells restricted to the epidermis (Paget disease).

The entire area of involved skin was excised to negative margins. Because of the size and location of the lesion, full thickness skin grafting was necessary for cosmetic closure. The carcinoma was restricted to the epidermis over a 1.7 cm area ([Fig. 4](#fig0020){ref-type="fig"}). The carcinoma was negative for ER, showed low levels of PR, and was strongly positive for HER2. No invasion was present. No evidence of an ectopic nipple, Toker cells, residual breast tissue, or apocrine glands was seen. Therefore the most likely source of the tumor cells was iatrogenic displacement of tumor cells from the breast into the epidermis from the prior core needle biopsy. The patient is without evidence of carcinoma, 3 years after the skin excision and 6 years after mastectomy.

3. Discussion {#sec0015}
=============

Adenocarcinoma between an intact basement membrane and an overlying normal epithelium is classified as Paget disease. The most common cause in the breast is DCIS extending from breast ducts into the epidermis of the nipple areolar complex. In the current case, the Paget disease was located away from the nipple and other etiologies had to be considered. Paget disease can arise from an ectopic nipple [@bib0010; @bib0015]. However, the location was far from the normal milk line along which ectopic nipples usually occur and a previously existing nipple was not observed. Extramammary Paget disease is thought to arise from apocrine glands, as it occurs in the genital, perianal, and axillary areas [@bib0020; @bib0025]. However, the recurrence was far from the axilla and no apocrine glands were present. Very rare cases of "ectopic" extramammary Paget disease occur in skin without apocrine glands and may arise from eccrine glands [@bib0030]. This disease most commonly involves the trunk of elderly males. No involvement of eccrine glands was seen in the current case.

The only likely remaining mechanism for this case of Paget disease is displacement of tumor cells from the original DCIS to the epidermis from tumor seeding the needle track. This possibility is supported by the identical histologic appearance and tumor marker expression of the original and recurrent carcinomas and the location at the core needle biopsy site.

Carcinoma recurring in a needle track as Paget disease of the skin has not been reported previously. There are only 13 other cases of breast cancer recurrence in a needle track after definitive surgery and a disease- free interval ([Table 1](#tbl0005){ref-type="table"}) [@bib0035; @bib0040; @bib0045; @bib0050; @bib0055; @bib0060; @bib0065]. Eleven of the cases were invasive cancers, one was DCIS, and one was not specified. The time to recurrence ranged from 1 to 6 years (average 2.5 years). Three patients who underwent breast conservation recurred as invasive carcinoma in the breast and 1 recurred in the skin. Seven of 9 patients who underwent mastectomy recurred as invasive carcinomas involving the skin and subcutaneous tissue. One patient recurred as invasive carcinoma in skeletal muscle. The site of recurrence was not specified for 1 patient. All but 1 patient had carcinoma limited to the core needle site. This patient had multiple foci of carcinoma in the dermis in the same quadrant [@bib0050]. She had presented with 3 invasive carcinomas and had undergone 3 core needle biopsies.

Epithelial displacement into needle tracks immediately after the procedure has been shown to be quite common [@bib0005; @bib0070]. How then, does one explain the scarcity of clinically evident recurrences? The likelihood of finding cells in the needle track diminishes over time, supporting that, in many cases, these cells do not persist, perhaps due to lack of a developed blood supply [@bib0075]. It is also possible that radiation therapy plays a role, as none of the patients with needle track recurrences received this therapy. The possible role of systemic therapy is less clear. Two patients received chemotherapy, 6 did not, and this information is not provided for the other 5 patients ([Table 1](#tbl0005){ref-type="table"}). Finally, removal of the needle track as part of the intended surgical resection or as a separate excision will eliminate any residual cells, though the utility of such a minor risk-reducing maneuver at the expense of likely cosmetic compromise may be debatable.

There are no definite risk factors for needle track recurrences. Needle track seeding has not been clearly associated with the type and size of needles, the number of needle passes, or the duration of the procedure [@bib0005]. Recurrences have been associated with both fine needle aspirations and core needle biopsies ([Table 1](#tbl0005){ref-type="table"}). Although 5 of the cancers were of special histologic types, this association may be related to the decision not to radiate rather than the type of cancer.

The rarity of clinically diagnosed needle track recurrences supports that routine excision of the skin and needle track is not required, especially for women undergoing radiation therapy. It has been suggested that it would be helpful to document the site of the biopsy with a diagram or photograph in the patient\'s medical record [@bib0060]. The location of the skin puncture site for a needle biopsy depends on the location of the lesion, the imaging modality used, and the size of the breast and cannot be determined with certainty unless recorded before the site heals. The need to document biopsy sites may be questioned due to the low number of reported recurrences. However, in the absence of knowing the location of the skin puncture, recurrences may be underreported. Documentation can also aid in early detection of recurrences. In the reported case, diagnosis was delayed for over a year as the skin lesion was mistaken for an infection. Fortunately, the carcinoma was detected while still in situ. Invasion can occur from Paget disease and the delay in diagnosis could have resulted in development of invasive carcinoma and a poorer prognosis [@bib0080; @bib0085].

The reported recurrences have been successfully treated with local excision and adjuvant treatment. Although follow-up is short, no cases have been reported with distant metastasis. It is important to recognize a skin recurrence as an isolated needle track recurrence, as this type of recurrence may not have the same dire prognosis for recurrent invasive carcinoma elsewhere in the chest wall [@bib0090; @bib0095].

4. Conclusions {#sec0020}
==============

Needle track recurrences after diagnosis and treatment of carcinoma are rare and have not been reported in patients receiving radiation therapy. For patients not receiving radiation, and whose needle track will not be removed by the planned surgery, documentation of the location of the skin puncture site in the patient\'s chart may be of value. This can aid in the early detection of a recurrence as a subcutaneous mass or as changes in the skin. Early detection, especially for recurrences as DCIS as in the described case, can avoid possible poor clinical outcomes.
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![This photograph was taken by the plastic surgeon as part of routine pre-surgical planning for breast reconstruction. The diagnostic core needle biopsy skin entrance site is visible in the lower inner quadrant of the right breast (arrow). The site is located away from the patient\'s nipple, which is normal in appearance, and no other skin lesions are present. It was fortuitous that the photograph was taken shortly after the core needle biopsy before the skin puncture site had healed.](gr1){#fig0005}

![One and a half years after mastectomy, the patient developed an erythematous skin lesion. Over the next several months, this lesion continued to increase in size (arrow). The nipple has been reconstructed.](gr2){#fig0010}

![Three years after mastectomy, the lesion had increased to a size of 2 cm and now appeared eroded (arrow). It was noted at this time that the lesion was present at the site of the prior core needle biopsy based on the clinical photograph in [Fig. 1](#fig0005){ref-type="fig"}. A skin punch biopsy was performed.](gr3){#fig0015}

![The skin punch biopsy and subsequent complete skin excision revealed tumor cells involving the epidermis. No invasion of the dermis was seen. There was no evidence of an ectopic nipple, apocrine glands, or eccrine gland involvement.](gr4){#fig0020}

###### 

Cases of recurrent cancer in the needle track after definitive surgical treatment.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         Biopsy type               Primary carcinoma                          ER        HER2      Surgery   XRT       Systemic treatment    Time to recurrence      Recurrent carcinoma                        Location of recurrence
  ----------------------------- ------------------------- ------------------------------------------ --------- --------- --------- --------- --------------------- ----------------------- ------------------------------------------ ------------------------------
  Thurfjell et al. [@bib0035]   FNA                       Adenoid cystic                             Unknown   Unknown   BCT       No        Unknown               4.1 years               Adenoid cystic                             Breast

  FNA                           Invasive mucinous         Unknown                                    Unknown   BCT       No        Unknown   2.5 years             Invasive mucinous       Breast                                     

  FNA                           Invasive tubuloductal     Unknown                                    Unknown   BCT       No        Unknown   2.1 years             Invasive tubuloductal   Breast                                     

  Chao et al. [@bib0040]        14G stereo CNB            Invasive ductal                            −         Unknown   M         No        Unknown               1.4 years               Invasive ductal                            Subcutaneous

  14G CNB                       Invasive ductal           \+                                         Unknown   M         No        AC, tam   1 year                Invasive ductal         Unknown                                    

  Intra et al. [@bib0045]       FNA\                      DCIS                                       \+        \+        M         No        No                    2 years                 Invasive ductal                            Muscle
                                CNB                                                                                                                                                                                                   

  Uriburu et al. [@bib0050]     14G stereo CNB            Invasive mucinous                          \+        Unknown   M SS      No        CMF                   1.9 years               Invasive with mucin                        Dermis and subcutaneous

  14G stereo CNB                Invasive ductal           \+                                         −         M SS      No        Unknown   1.8 years             Invasive ductal         Dermis and subcutaneous                    

  14G stereo CNB                Invasive ductal           \+                                         \+        M SS      No        Unknown   1.3 years             Invasive ductal         Subcutaneous                               

  Kwo and Grotting [@bib0055]   CNB                       Not specified                              Unknown   Unknown   M SS      No        No                    6 years                 Not specified                              Skin

  Brouwer et al. [@bib0060]     14G CNB                   Invasive ductal                            \+        \+        M SS      No        No                    1.1 years               Invasive ductal                            Skin and dermis

                                Invasive ductal/lobular   \+                                         −         M SS      No        No        1.2 years             Invasive                Skin and dermis                            

  Kawasaki et al. [@bib0065]    16G CNB                   Well differentiated neuroendocrine tumor   \+        −         BCT       No        Aromatase inhibitor   3.9 years               Well differentiated neuroendocrine tumor   Skin and subcutaneous tissue

  Current study                 10G stereo CNB            DCIS with microinvasion                    −         \+        M SS      No        No                    1.5 years               Paget disease (DCIS)                       Epidermis
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FNA, fine needle aspiration; stereo CNB, stereotactic core needle biopsy; DCIS, ductal carcinoma in situ; ER, estrogen receptor; BCT, breast conserving therapy; M, mastectomy; SS, skin sparing; XRT, radiation therapy; CMF, cyclophosphamide, methotrexate, and 5-fluorocuracil; AC, adriamycin, cytoxan; tam, tamoxifen.
